These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8669314)

  • 1. [Arterial hypertension, left ventricular hypertrophy and cardiovascular risk].
    Nogueira JB
    Acta Med Port; 1995 Dec; 8(12):663-6. PubMed ID: 8669314
    [No Abstract]   [Full Text] [Related]  

  • 2. [Arterial hypertension, correlated factors and cardiovascular risk].
    Pessina AC; Casiglia E; Rossi GP; Semplicini A
    Cardiologia; 1991 Dec; 36(12 Suppl 1):67-78. PubMed ID: 1841807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial hypertension and cardiovascular damage in the elderly: focus on arterial stiffness and left ventricular hypertrophy.
    Paciaroni E; Antonicelli R; Gambini C; Sirolla C
    Clin Exp Hypertens; 1993; 15 Suppl 1():1-7. PubMed ID: 8513302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular hypertrophy: a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure.
    Mansoor GA; Massie BM
    Blood Press Monit; 1999; 4 Suppl 1():S19-22. PubMed ID: 10822413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypertension, coronary disease and impact of arterial hypertension on results of coronary surgery].
    Christenson JT; Simonet F; Schmuziger M
    Praxis (Bern 1994); 1997 Jan; 86(1-2):9-12. PubMed ID: 9045280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 9. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
    Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular abnormalities in patients with obstructive sleep apnoea syndrome].
    Myśliński W; Dybała A; Mosiewicz J; Prystupa A; Hanzlik J
    Wiad Lek; 2005; 58(1-2):78-83. PubMed ID: 15991558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
    Amabile G
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aging hypertensive heart: a brief update.
    Susic D; Frohlich ED
    Nat Clin Pract Cardiovasc Med; 2008 Feb; 5(2):104-10. PubMed ID: 18223542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Left ventricular hypertrophy regression in arterial hypertension. The efficacy of the angiotensin II type 1 receptor antagonists].
    González-Juanatey JR; Vallés Belsué F
    Med Clin (Barc); 2000; 114 Suppl 1():39-42. PubMed ID: 10812574
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiac failure in hypertensive cardiopathy].
    Verdecchia P
    Ital Heart J; 2000 Jun; 1 Suppl 2():72-7. PubMed ID: 10905132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On the connection between left ventricular hypertrophy and diastolic dysfunction in arterial hypertension].
    Trushinskiĭ ZK; Dovgaliuk IuV; Skritskaia OIu
    Ter Arkh; 2003; 75(3):57-9. PubMed ID: 12718223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arrhythmia risk in left ventricular hypertrophy].
    Perings C; Hennersdorf M; Vester EG; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():36-43. PubMed ID: 10810783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular hypertrophy as a risk factor in hypertension.
    Balogun MO; Dunn FG
    Afr J Med Med Sci; 1996 Sep; 25(3):277-83. PubMed ID: 10457806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New cardiovascular risk factors and chronic kidney disease. Hypertrophy of the left ventricle. Atrial fibrillation. Smoking. Obesity. Emerging cardiovascular risk factors: homocysteine, Reactive C protein. Fibrinogen].
    Cases A
    Nefrologia; 2004; 24 Suppl(6):62-72, 187-235. PubMed ID: 15696897
    [No Abstract]   [Full Text] [Related]  

  • 20. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.